35 completed, 3 terminated, 3 unknown, 2 not yet recruiting. 45 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 45 | Completed 35, Terminated 3, Unknown 3, Not yet recruiting 2, Withdrawn 2 |
Follow Brimonidine Tartrate: new trials by email Literature Review of Brimonidine Tartrate trials Research Report on Brimonidine Tartrate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Effect of Lumify™ on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients brimonidine tartrate ophthalmic solution 0.025%, sterile balanced saline solution - Glaucoma, Glaucoma, Open-Angle | Phase 4 | Not yet recruiting | Tulane University | 60 | 2027-11-01 | 2026-10-13 |
| Upneeq vs. Lumify Ptosis Oxymetazoline 0.1% (Upneeq), Brimonidine 0.025% (Lumify) - Acquired Ptosis | Phase 4 | Not yet recruiting | Duke University | 50 | 2026-12-01 | 2026-05-22 |
| Brimonidine 0.33% for Rosacea-Related Facial Erythema Brimonidine 0.33% gel, Placebo gel - Rosacea, Rosacea Subtype 1 (Erythematotelangiectatic) | Phase 4 | Completed | Istanbul Training and Research Hospital | 45 | 2025-05-01 | 2026-02-24 |
| Effect of Netarsudil vs Brimonidine in NTG Patients on Latanoprost Netarsudil, Brimonidine - Normal Tension Glaucoma | Phase 4 | Completed | Westlake Eye Specialists | 100 | 2024-06-13 | 2025-10-22 |
| Brimonidine for Intraoperative Hemostasis Brimonidine Topical - Dermatochalasis of Eyelid, Ptosis, Eyelid | Phase 4 | Withdrawn | University of Louisville | 2022-05-26 | 2025-01-15 | |
| Comparison of Efficacy and Ocular Surface Assessment Between BRIDIN-plus and Combigan in Glaucoma or Ocular Hypertensive BRIDIN-plus Eye drops, Combigan Eye drops - Glaucoma, Ocular Hypertensive | Phase 4 | Completed | CHA University | 60 | 2021-10-08 | 2025-03-26 |
| The Effect of Topical Brimonidine on the Ocular Hemodynamics in Patients of POAG Using OCTA Brimonidine tartrate 0.2% ophthalmic solution - Glaucoma, Primary Open Angle, Ocular Blood Flow | Phase 4 | Completed | Fayoum University | 41 | 2020-05-01 | 2022-07-26 |
| The Effect of Brimonidine Brimonidine, Tropicamide, Phenylephrine Ophthalmic Product - Intraocular Pressure | Phase 4 | Completed | Wake Forest University Health Sciences | 13 | 2019-07-20 | 2024-02-01 |
| The Effect of Lumify™ Eyedrops on Eyelid Position Brimonidine tartrate ophthalmic solution 0.025%, Sterile balanced saline solution - Eyelid Droop | Phase 4 | Completed | University of Miami | 43 | 2019-06-18 | 2021-06-14 |
| Comparison of Efficacy and Ocular Surface Disease Assessment Between BRIDIN-T Eye Drops 0.15% and ALPHAGAN-P Eye Drops 0.15% in Glaucoma or Ocular Hypertensive Patients : Phase 4, Parallel Group Design, Investigator-blind, Active-control, Randomized, Multi-center Trial Brimonidine Tartrate 1.5mg - Glaucoma, Ocular Hypertensive | Phase 4 | Unknown | CHA University | 61 | 2019-03-20 | 2020-12-01 |
| Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma brinzolamide 1%/brimonidine 0.2% fixed combination, Placebo, travoprost 0.004% ophthalmic solution - Glaucoma | Phase 4 | Completed | Novartis Pharmaceuticals | 1 | 2017-09-21 | 2019-02-25 |
| Peripapillary Blood Flow After Use of Anti-glaucoma Medications: An OCT Angiography Study Timolol Maleate, Brimonidine Tartrate - Glaucoma; Drugs, Normal Tension Glaucoma | Phase 4 | Completed | Wills Eye | 35 | 2017-07-10 | 2020-12-31 |
| Efficacy and Safety of COMBIGAN® in Korean Patients With Primary Open Angle Glaucoma (POAG) and Normal Tension Glaucoma (NTG) brimonidine tartrate/timolol malate Ophthalmic Solution, bimatoprost ophthalmic solution 0.01% - Glaucoma, Open-Angle, Normal Tension Glaucoma | Phase 4 | Completed | Allergan | 118 | 2016-07-05 | 2018-08-31 |
| Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV® Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, Brinzolamide/brimonidine vehicle, Travoprost 0.004%/timolol 0.5% solution - Open-angle Glaucoma, Ocular Hypertension | Phase 4 | Terminated | Alcon Research | 173 | 2016-06-24 | 2019-05-29 |
| Brinzolamide/Brimonidine Combination vs Brimonidine 0.2% in the Prevention of IOP Rise After Nd-YAG Laser Capsulotomy Brinzolamide/Brimonidine FC, Brimonidine 0.2%, Artificial tears - Posterior Capsule Opacification, Ocular Hypertension | Phase 4 | Completed | University Hospital of Patras | 79 | 2016-06-20 | 2019-07-16 |
| A Multicenter, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Once Daily Mirvaso® Gel in Patients With Chronic Persistent Vascular Facial Erythema. brimonidine tartrate - Chronic Persistent Vascular Facial Erythema | Phase 4 | Completed | Galderma Brasil Ltda. | 101 | 2016-06-13 | 2017-04-06 |
| 24-hr Intraocular Pressure Control With SIMBRINZA ® Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension, Vehicle - Glaucoma | Phase 4 | Completed | Alcon Research | 162 | 2016-05-23 | 2018-07-02 |
| Internet Surveys and Their Impact on Adherence for Rosacea brimonidine topical gel 0.33% & survey, brimonidine topical gel 0.33% & SOC - Rosacea | Phase 4 | Completed | Wake Forest University Health Sciences | 20 | 2016-05-05 | 2018-10-10 |
| Topical Brimonidine to Reduce Inflammation After IPL-treatment in Patients With Facial Telangiectasias Brimonidine, IPL+air-cooling - Telangiectasias | Phase 4 | Completed | Merete Haedersdal | 19 | 2016-03-13 | 2018-01-05 |
| Preoperative Brimonidine on IOP of Patients Undergoing RALP brimonidine tartrate 0.2%, Carboxymethylcellulose Eye Drops - Prostate Cancer | Phase 4 | Completed | University Health Network, Toronto | 26 | 2016-02-29 | 2018-09-27 |
Showing 20 of 45. Sign in to see all of them.
Glaucoma (17) · Glaucoma, Open-Angle (16) · Ocular Hypertension (12) · Low Tension Glaucoma (5) · Blepharoptosis (4) · Rosacea (4) · Telangiectasis (2) · Depression (1) · Ectropion (1) · Entropion (1) · Erythema (1) · Glaucoma, Angle-Closure (1) · Inflammation (1) · Injection Site Reaction (1) · Multiple Sclerosis, Relapsing-Remitting (1)
Alcon Research (7) · Allergan (6) · Aristotle University Of Thessaloniki (2) · Bp Consulting, Inc (2) · CHA University (2) · Galderma R&D (2) · Wake Forest University Health Sciences (2) · Afyon Kocatepe University Hospital (1) · Biogen (1) · Credit Valley EyeCare (1) · Duke University (1) · Fayoum University (1) · Federal University of São Paulo (1) · Galderma Brasil Ltda. (1) · Innovative Medical (1)
United States (17) · Canada (5) · South Korea (5) · Greece (2) · Austria (1) · Brazil (1) · China (1) · Denmark (1) · Egypt (1) · Italy (1) · Thailand (1) · Turkey (Türkiye) (1)
Steve Burmaster, PhD (2) · Aline K Sousa, MD (1) · Amandeep S Rai, MD (1) · Anastasios G Konstas, MD, PhD (1) · Anastasios Konstas, MD, phD (1) · Buys M Yvonne, MD FRCSC (1) · Christopher Compton, MD (1) · Christopher Dermarkarian (1) · Constantinos Georgakopoulos, MD, PhD (1) · Daniel Lee, MD (1)
PMID 19476406, PMID 18402717, PMID 21960068, PMID 23839181
2015 (3), 2016 (1)